Technical Analysis for RPRX - Royalty Pharma plc
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 26.78 | 0.30% | 0.08 |
RPRX closed up 0.3 percent on Thursday, September 28, 2023, on 74 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Shooting Star Candlestick | Bearish | 0.00% | |
1,2,3 Retracement Bearish | Bearish Swing Setup | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
Calm After Storm | Range Contraction | 0.00% | |
Gapped Up | Strength | 0.30% | |
Oversold Stochastic | Weakness | 0.30% | |
1,2,3 Retracement Bearish | Bearish Swing Setup | 0.15% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.15% | |
Calm After Storm | Range Contraction | 0.15% | |
Up 3 Days in a Row | Strength | 0.15% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
10 DMA Resistance | about 10 hours ago |
Rose Above 10 DMA | about 10 hours ago |
60 Minute Opening Range Breakout | about 11 hours ago |
Up 1% | about 11 hours ago |
Down 1% | 1 day ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/06/2023
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Pharmaceutical Products Drug Development HIV Biopharmaceutical Products
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Pharmaceutical Products Drug Development HIV Biopharmaceutical Products
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 43.6712 |
52 Week Low | 25.92 |
Average Volume | 2,042,913 |
200-Day Moving Average | 33.66 |
50-Day Moving Average | 29.44 |
20-Day Moving Average | 28.14 |
10-Day Moving Average | 27.04 |
Average True Range | 0.62 |
RSI (14) | 29.58 |
ADX | 31.55 |
+DI | 14.13 |
-DI | 33.02 |
Chandelier Exit (Long, 3 ATRs) | 29.00 |
Chandelier Exit (Short, 3 ATRs) | 27.79 |
Upper Bollinger Bands | 30.60 |
Lower Bollinger Band | 25.68 |
Percent B (%b) | 0.22 |
BandWidth | 17.50 |
MACD Line | -0.88 |
MACD Signal Line | -0.77 |
MACD Histogram | -0.1192 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 27.43 | ||||
Resistance 3 (R3) | 27.45 | 27.27 | 27.32 | ||
Resistance 2 (R2) | 27.27 | 27.10 | 27.25 | 27.28 | |
Resistance 1 (R1) | 27.02 | 27.00 | 27.15 | 27.00 | 27.25 |
Pivot Point | 26.84 | 26.84 | 26.90 | 26.82 | 26.84 |
Support 1 (S1) | 26.59 | 26.67 | 26.72 | 26.57 | 26.31 |
Support 2 (S2) | 26.41 | 26.57 | 26.39 | 26.28 | |
Support 3 (S3) | 26.16 | 26.41 | 26.24 | ||
Support 4 (S4) | 26.14 |